Randomized, multicenter, phase iii, open-label study of Alectinib versus Crizotinib in treatment-naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer
- Briggs, Peter (Primary Chief Investigator (PCI))
Project: Research
Project: Research